ENDOLOGIX INC's ticker is and the CUSIP is 29266SAB2. A total of 8 filers reported holding ENDOLOGIX INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $17,319,000 | +0.3% | 25,563,000 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $17,266,000 | +6.2% | 25,563,000 | +7.5% | 0.01% | +28.6% |
| Q3 2018 | $16,265,000 | -6.0% | 23,788,000 | +26.1% | 0.01% | -22.2% |
| Q2 2018 | $17,304,000 | +8.5% | 18,860,000 | +1.6% | 0.01% | 0.0% |
| Q1 2018 | $15,955,000 | -5.6% | 18,560,000 | 0.0% | 0.01% | -10.0% |
| Q4 2017 | $16,896,000 | +6.5% | 18,560,000 | 0.0% | 0.01% | -16.7% |
| Q3 2017 | $15,866,000 | +13.0% | 18,560,000 | +10.5% | 0.01% | 0.0% |
| Q2 2017 | $14,043,000 | -15.2% | 16,800,000 | 0.0% | 0.01% | -20.0% |
| Q1 2017 | $16,555,000 | -40.5% | 16,800,000 | -47.2% | 0.02% | -46.4% |
| Q4 2016 | $27,808,000 | -24.6% | 31,800,000 | +14.4% | 0.03% | -24.3% |
| Q3 2016 | $36,886,000 | +21.2% | 27,800,000 | +19.3% | 0.04% | +8.8% |
| Q2 2016 | $30,423,000 | +64.2% | 23,300,000 | +20.7% | 0.03% | +47.8% |
| Q1 2016 | $18,532,000 | +0.2% | 19,300,000 | +13.5% | 0.02% | +15.0% |
| Q4 2015 | $18,501,000 | – | 17,000,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 3,500,000 | $3,793,000 | 5.91% |
| FNY Managed Accounts LLC | 500,000 | $542,190,000 | 2.68% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 30,000,000 | $32,548,000 | 1.32% |
| ZAZOVE ASSOCIATES LLC | 13,906,000 | $15,123,000 | 0.71% |
| DAFNA Capital Management LLC | 500,000 | $545,000 | 0.49% |
| SSI INVESTMENT MANAGEMENT LLC | 4,000,000 | $4,308,000 | 0.44% |
| CAMDEN ASSET MANAGEMENT L P /CA | 9,100,000 | $9,868,000 | 0.31% |
| LINDEN ADVISORS LP | 4,500,000 | $4,896,000 | 0.30% |
| WOLVERINE ASSET MANAGEMENT LLC | 11,000,000 | $11,949,000 | 0.26% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 300,000 | $327,000 | 0.05% |